Legend Biotech Corp
LEGN32.030USD
+0.440+1.39%
Close 11/11, 16:00（ET）Quotes delayed by 15 min
5.91BMarket Cap
LossP/E TTM
More Details of Legend Biotech Corp Company
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Legend Biotech Corp Info
Ticker SymbolLEGN
Company nameLegend Biotech Corp
IPO dateJun 04, 2020
CEODr. Ying Huang, Ph.D.
Number of employees2600
Security typeDepository Receipt
Fiscal year-endJun 04
Address2101 Cottontail Lane
CitySOMERSET
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code08873
Phone17328505598
Websitehttps://investors.legendbiotech.com/
Ticker SymbolLEGN
IPO dateJun 04, 2020
CEODr. Ying Huang, Ph.D.
Company Executives of Legend Biotech Corp
Name
Name/Position
Position
Shareholding
Change
Ms. Ye (Sally) Wang
Ms. Ye (Sally) Wang
Director
Director
84.32K
--
Dr. Li Mao
Dr. Li Mao
Independent Director
Independent Director
7.62K
--
Dr. Li Zhu, Ph.D.
Dr. Li Zhu, Ph.D.
Director
Director
4.20K
--
Mr. Xiaohui (Darren) Ji
Mr. Xiaohui (Darren) Ji
Independent Director
Independent Director
--
--
Ms. Jessie Yeung
Ms. Jessie Yeung
Director
Director
--
--
Dr. Peter Salovey, Ph.D.
Dr. Peter Salovey, Ph.D.
Independent Director
Independent Director
--
--
Mr. Wai Man (Philip) Yau, CPA
Mr. Wai Man (Philip) Yau, CPA
Independent Director
Independent Director
--
--
Dr. Ying Huang, Ph.D.
Dr. Ying Huang, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
-100.00%
Mr. Tomas J. (Tom) Heyman, Jr.
Mr. Tomas J. (Tom) Heyman, Jr.
Independent Director
Independent Director
--
--
Dr. Fangliang (Frank) Zhang, Ph.D.
Dr. Fangliang (Frank) Zhang, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Ye (Sally) Wang
Ms. Ye (Sally) Wang
Director
Director
84.32K
--
Dr. Li Mao
Dr. Li Mao
Independent Director
Independent Director
7.62K
--
Dr. Li Zhu, Ph.D.
Dr. Li Zhu, Ph.D.
Director
Director
4.20K
--
Mr. Xiaohui (Darren) Ji
Mr. Xiaohui (Darren) Ji
Independent Director
Independent Director
--
--
Ms. Jessie Yeung
Ms. Jessie Yeung
Director
Director
--
--
Dr. Peter Salovey, Ph.D.
Dr. Peter Salovey, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
No Data
By RegionUSD
Name
Revenue
Proportion
United States
194.60M
76.30%
Europe
40.50M
15.88%
China
19.95M
7.82%
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Oct 24
Updated: Fri, Oct 24
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
12.53%
Westfield Capital Management Company, L.P.
3.51%
HHLR Advisors, Ltd.
3.36%
Suvretta Capital Management, LLC
2.04%
Deerfield Management Company, L.P.
1.60%
Other
76.95%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
12.53%
Westfield Capital Management Company, L.P.
3.51%
HHLR Advisors, Ltd.
3.36%
Suvretta Capital Management, LLC
2.04%
Deerfield Management Company, L.P.
1.60%
Other
76.95%
Shareholder Types
Shareholders
Proportion
Investment Advisor
22.63%
Investment Advisor/Hedge Fund
13.58%
Hedge Fund
8.80%
Corporation
1.22%
Research Firm
1.13%
Venture Capital
0.59%
Pension Fund
0.40%
Bank and Trust
0.29%
Sovereign Wealth Fund
0.20%
Other
51.16%
Institutional Shareholding
Updated: Sun, Oct 5
Updated: Sun, Oct 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
547
88.17M
47.77%
-17.67M
2025Q2
545
89.45M
48.54%
-25.68M
2025Q1
566
91.15M
49.68%
-26.78M
2024Q4
546
104.37M
56.89%
-4.12M
2024Q3
521
96.19M
52.43%
-11.10M
2024Q2
501
96.66M
52.77%
-1.31M
2024Q1
490
91.55M
50.22%
-3.47M
2023Q4
482
91.08M
50.06%
-4.11M
2023Q3
468
90.50M
49.93%
-2.81M
2023Q2
459
88.99M
49.23%
+9.84M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
23.13M
12.53%
+11.87M
+105.49%
Jun 30, 2025
Westfield Capital Management Company, L.P.
6.47M
3.51%
-445.02K
-6.43%
Jun 30, 2025
HHLR Advisors, Ltd.
6.20M
3.36%
+218.70K
+3.65%
Jun 30, 2025
Suvretta Capital Management, LLC
3.77M
2.04%
+24.04K
+0.64%
Jun 30, 2025
Deerfield Management Company, L.P.
2.96M
1.6%
+1.22M
+69.90%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.85M
1.55%
-255.88K
-8.23%
Jun 30, 2025
Braidwell LP
2.54M
1.38%
-435.85K
-14.64%
Jun 30, 2025
Fidelity Institutional Asset Management
2.54M
1.38%
+593.12K
+30.44%
Jun 30, 2025
Genscript Biotech Corp
2.25M
1.22%
--
--
Dec 31, 2024
Artisan Partners Limited Partnership
2.12M
1.15%
+990.50K
+87.52%
Jun 30, 2025
View more
Related ETFs
Updated: Sun, Nov 2
Updated: Sun, Nov 2
Name
Proportion
Harbor Health Care ETF
6.42%
Matthews Emerging Markets Discovery Active ETF
4.32%
Matthews Emerging Markets Sustainable Future Active ETF
4.16%
Global X Genomics & Biotechnology ETF
3.38%
Tema Oncology ETF
2.53%
Virtus LifeSci Biotech Products ETF
1.43%
KraneShares MSCI All China Health Care Index ETF
1.25%
Main Thematic Innovation ETF
0.45%
iShares Biotechnology ETF
0.39%
Invesco Nasdaq Biotechnology ETF
0.28%
View more
Harbor Health Care ETF
Proportion6.42%
Matthews Emerging Markets Discovery Active ETF
Proportion4.32%
Matthews Emerging Markets Sustainable Future Active ETF
Proportion4.16%
Global X Genomics & Biotechnology ETF
Proportion3.38%
Tema Oncology ETF
Proportion2.53%
Virtus LifeSci Biotech Products ETF
Proportion1.43%
KraneShares MSCI All China Health Care Index ETF
Proportion1.25%
Main Thematic Innovation ETF
Proportion0.45%
iShares Biotechnology ETF
Proportion0.39%
Invesco Nasdaq Biotechnology ETF
Proportion0.28%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
